Toxic neuropathy

Thirugnanam Umapathi, Vinay Chaudhry

Research output: Contribution to journalArticle

Abstract

Purpose of review: This paper examinee recent research on toxic neuropathy and potential therapeutic developments. It also summarizes reports of new agents reported to cause peripheral neuropathy. Recent findings: Gene therapy with vasoactive endothelial growth factor, neurotrophic substances such as nerve growth factor and neurotrophin-3 are reported to reverse or protect against neurotoxicity in animal models. The neuroprotective effects of more established therapeutic agents like vitamin E, tacrolimus (FK 506) and erythropoietin hold promise for the immediate future. Cisplatin and high-dose pyridoxine are used more frequently to produce robust models of peripheral neuropathy in animals. Statins do appear to cause peripheral neuropathy. The incidence is low, however, and compared to its benefits in terms of cardiovascular protection, relatively innocuous. The profile of thalidomide neuropathy is becoming clearer as the indications for this drug increases. The incidence of thalidomide neuropathy is high, up to three quarters in some series, and although the information on dose dependency is variable, lower cumulative doses appear to be less toxic. Like thalidomide bortezomib, a novel proteosome inhibitor, is reportedly effective in the treatment of multiple myeloma and is associated with peripheral neuropathy. Oxaliplatin and epothilone are emerging anticancer drugs with neurotoxic potential. Similarly, leflunomide, a new disease modifying-agent approved for the treatment of rheumatoid arthritis, is reported to cause neuropathy. Summary: The study of toxic neuropathy is not only enhancing our knowledge of the mechanisms of neurotoxicity but also the neurobiology of peripheral neuropathy in general; and is likely to reveal avenues for therapeutics.

Original languageEnglish (US)
Pages (from-to)574-580
Number of pages7
JournalCurrent Opinion in Neurology
Volume18
Issue number5
StatePublished - Oct 2005
Externally publishedYes

Fingerprint

Poisons
Peripheral Nervous System Diseases
Thalidomide
oxaliplatin
leflunomide
Tacrolimus
Epothilones
Endothelial Growth Factors
Neurotrophin 3
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pyridoxine
Neurobiology
Incidence
Neuroprotective Agents
Nerve Growth Factor
Erythropoietin
Multiple Myeloma
Vitamin E
Pharmaceutical Preparations

Keywords

  • Chemotherapy agents
  • Erythropoietin
  • FK-506
  • Gene therapy
  • Neuropathy models
  • Neurotrophic factors
  • Statin
  • Toxic neuropathy
  • VEGF
  • Vitamin E

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Umapathi, T., & Chaudhry, V. (2005). Toxic neuropathy. Current Opinion in Neurology, 18(5), 574-580.

Toxic neuropathy. / Umapathi, Thirugnanam; Chaudhry, Vinay.

In: Current Opinion in Neurology, Vol. 18, No. 5, 10.2005, p. 574-580.

Research output: Contribution to journalArticle

Umapathi, T & Chaudhry, V 2005, 'Toxic neuropathy', Current Opinion in Neurology, vol. 18, no. 5, pp. 574-580.
Umapathi T, Chaudhry V. Toxic neuropathy. Current Opinion in Neurology. 2005 Oct;18(5):574-580.
Umapathi, Thirugnanam ; Chaudhry, Vinay. / Toxic neuropathy. In: Current Opinion in Neurology. 2005 ; Vol. 18, No. 5. pp. 574-580.
@article{f412a3e36498416da4bb2c5f14363791,
title = "Toxic neuropathy",
abstract = "Purpose of review: This paper examinee recent research on toxic neuropathy and potential therapeutic developments. It also summarizes reports of new agents reported to cause peripheral neuropathy. Recent findings: Gene therapy with vasoactive endothelial growth factor, neurotrophic substances such as nerve growth factor and neurotrophin-3 are reported to reverse or protect against neurotoxicity in animal models. The neuroprotective effects of more established therapeutic agents like vitamin E, tacrolimus (FK 506) and erythropoietin hold promise for the immediate future. Cisplatin and high-dose pyridoxine are used more frequently to produce robust models of peripheral neuropathy in animals. Statins do appear to cause peripheral neuropathy. The incidence is low, however, and compared to its benefits in terms of cardiovascular protection, relatively innocuous. The profile of thalidomide neuropathy is becoming clearer as the indications for this drug increases. The incidence of thalidomide neuropathy is high, up to three quarters in some series, and although the information on dose dependency is variable, lower cumulative doses appear to be less toxic. Like thalidomide bortezomib, a novel proteosome inhibitor, is reportedly effective in the treatment of multiple myeloma and is associated with peripheral neuropathy. Oxaliplatin and epothilone are emerging anticancer drugs with neurotoxic potential. Similarly, leflunomide, a new disease modifying-agent approved for the treatment of rheumatoid arthritis, is reported to cause neuropathy. Summary: The study of toxic neuropathy is not only enhancing our knowledge of the mechanisms of neurotoxicity but also the neurobiology of peripheral neuropathy in general; and is likely to reveal avenues for therapeutics.",
keywords = "Chemotherapy agents, Erythropoietin, FK-506, Gene therapy, Neuropathy models, Neurotrophic factors, Statin, Toxic neuropathy, VEGF, Vitamin E",
author = "Thirugnanam Umapathi and Vinay Chaudhry",
year = "2005",
month = "10",
language = "English (US)",
volume = "18",
pages = "574--580",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Toxic neuropathy

AU - Umapathi, Thirugnanam

AU - Chaudhry, Vinay

PY - 2005/10

Y1 - 2005/10

N2 - Purpose of review: This paper examinee recent research on toxic neuropathy and potential therapeutic developments. It also summarizes reports of new agents reported to cause peripheral neuropathy. Recent findings: Gene therapy with vasoactive endothelial growth factor, neurotrophic substances such as nerve growth factor and neurotrophin-3 are reported to reverse or protect against neurotoxicity in animal models. The neuroprotective effects of more established therapeutic agents like vitamin E, tacrolimus (FK 506) and erythropoietin hold promise for the immediate future. Cisplatin and high-dose pyridoxine are used more frequently to produce robust models of peripheral neuropathy in animals. Statins do appear to cause peripheral neuropathy. The incidence is low, however, and compared to its benefits in terms of cardiovascular protection, relatively innocuous. The profile of thalidomide neuropathy is becoming clearer as the indications for this drug increases. The incidence of thalidomide neuropathy is high, up to three quarters in some series, and although the information on dose dependency is variable, lower cumulative doses appear to be less toxic. Like thalidomide bortezomib, a novel proteosome inhibitor, is reportedly effective in the treatment of multiple myeloma and is associated with peripheral neuropathy. Oxaliplatin and epothilone are emerging anticancer drugs with neurotoxic potential. Similarly, leflunomide, a new disease modifying-agent approved for the treatment of rheumatoid arthritis, is reported to cause neuropathy. Summary: The study of toxic neuropathy is not only enhancing our knowledge of the mechanisms of neurotoxicity but also the neurobiology of peripheral neuropathy in general; and is likely to reveal avenues for therapeutics.

AB - Purpose of review: This paper examinee recent research on toxic neuropathy and potential therapeutic developments. It also summarizes reports of new agents reported to cause peripheral neuropathy. Recent findings: Gene therapy with vasoactive endothelial growth factor, neurotrophic substances such as nerve growth factor and neurotrophin-3 are reported to reverse or protect against neurotoxicity in animal models. The neuroprotective effects of more established therapeutic agents like vitamin E, tacrolimus (FK 506) and erythropoietin hold promise for the immediate future. Cisplatin and high-dose pyridoxine are used more frequently to produce robust models of peripheral neuropathy in animals. Statins do appear to cause peripheral neuropathy. The incidence is low, however, and compared to its benefits in terms of cardiovascular protection, relatively innocuous. The profile of thalidomide neuropathy is becoming clearer as the indications for this drug increases. The incidence of thalidomide neuropathy is high, up to three quarters in some series, and although the information on dose dependency is variable, lower cumulative doses appear to be less toxic. Like thalidomide bortezomib, a novel proteosome inhibitor, is reportedly effective in the treatment of multiple myeloma and is associated with peripheral neuropathy. Oxaliplatin and epothilone are emerging anticancer drugs with neurotoxic potential. Similarly, leflunomide, a new disease modifying-agent approved for the treatment of rheumatoid arthritis, is reported to cause neuropathy. Summary: The study of toxic neuropathy is not only enhancing our knowledge of the mechanisms of neurotoxicity but also the neurobiology of peripheral neuropathy in general; and is likely to reveal avenues for therapeutics.

KW - Chemotherapy agents

KW - Erythropoietin

KW - FK-506

KW - Gene therapy

KW - Neuropathy models

KW - Neurotrophic factors

KW - Statin

KW - Toxic neuropathy

KW - VEGF

KW - Vitamin E

UR - http://www.scopus.com/inward/record.url?scp=26944446961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26944446961&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 574

EP - 580

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

IS - 5

ER -